UBI集團訊息
United BioPharma had received the “2017 Potential Benchmark Award"
United BioPharma was established in September, 2013, and quickly established itself to become the best and leading company in Taiwan. The company has more than 150 employees and its manufacturing plant covers a total area of 22000 square meters. The capability of the fermentation process is up to 3-8 g/L. The concentration of subcutaneous injection of antibody drugs is up to 150 mg / mL. The capability of various techniques have reached international standards. United BioPharma owns several pipeline products in different fields including infectious disease, oncology and immune diseases. UBP’s leading product, UB-421, has applied to TFDA for a Phase III clinical trial in HAART substitution.They will also apply to the US FDA for a Phase IIb/III clinical trial in HAART Failure in May.
United BioPharma has demonstrated its outstanding performance in innovation, R & D, future potential and the contribution to the biopharmaceutical industry. It has been awarded the “Potential Benchmark Award" by the Taiwan Bioindustry Development Association to recognize its business performance and innovative technologies to serve as a benchmark for industrial development.
About United BioPharma (6471)
United BioPharma (UBP) was established in September 2013 as a spinoff from United Biomedical, Inc., Asia, and is strategically partnered with Formosa Plastics Group. UBP has an integrated monoclonal antibody drug development platform, and focuses on development, manufacturing, and marketing of innovative monoclonal antibody drugs and biosimilars. With a spirit of “innovation and practicality,” UBP is dedicated to addressing unmet medical needs to improve the health of mankind.
United BioPharma Forward-Looking Statements
The information in this press release should be considered accurate only as of the date of the release. UBP has no intention of updating and specifically disclaims any duty to update the information in this press release. The press release may contain forward-looking statements involving risks and uncertainties and UBP’s actual results may differ materially from those in the forward-looking statements.